我国恶性疟原虫主要药物抗性研究

doi:10.12140/j.issn.1000-7423.2020.05.016

摘要/Abstract

摘要：

疟疾广泛流行于热带和亚热带地区,是非洲和东南亚地区重要的公共卫生问题之一。我国自2017年以来,已无本地疟疾病例报告,但如何做好境外恶性疟输入病例救治及抗疟药物监测,防止输入病例引起的本地病例发生或暴发尤为重要。抗疟药物作为疟疾防治的主要手段之一,有效遏制了全球疟疾流行,但随着抗疟药物的长期使用,恶性疟原虫耐药性问题,特别是对青蒿素类药物耐药性问题是目前疟疾防控的难题之一,本文就我国恶性疟原虫对主要抗疟药物抗性研究进行综述。

关键词: 恶性疟原虫, 抗疟疾药物抗性, 青蒿素类药物

Abstract:

Malaria is prevalent in tropical and subtropical regions, and is one of the public health problems in Africa and Southeast Asia. Although since 2017 there has been no indigenous malaria cases reported in China, it is still of particular importance to treat and care imported falciparum malaria cases, monitor anti-malarial drugs, and prevent the occurrence or outbreak of local cases caused by imported cases. The anti-malarial drugs have long been one of the main approaches for malaria control and have effectively controlled the global transmission of malaria. However, with the long-term use of anti-malarial drugs, the problem of drug resistance of P. falciparum, particularly the resistance to artemisinin drugs, has become one of the major challenges for malaria prevention and control at present. In this review, we summarize the researches on the resistance of P. falciparum to some main anti-malarial drugs in China.

Key words: Plasmodium falciparum, Resistance to anti-malarial drug, Artemisinin drugs

中图分类号:

R382.312

叶升玉, 成依依, 李曼, 周红宁. 我国恶性疟原虫主要药物抗性研究[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(5): 631-636.

YE Sheng-yu, CHENG Yi-yi, LI Man, ZHOU Hong-ning. An overview on the resistance of Plasmodium falciparum to primary anti-malarial drugs in China[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2020, 38(5): 631-636.

参考文献 59

[1]	World Health Organization. World malaria report 2019[R]. Geneva: World Health Organization, 2019.
[2]	Marsh K. Malaria disaster in Africa[J]. Lancet, 1998,352(9132):924.
[3]	Harinasuta T, Suntharasamai P, Viravan C. Chloroquine-resistant falciparum malaria in Thailand[J]. Lancet, 1965,2(7414):657-660.
[4]	Thu AM, Phyo AP, Landier J, et al. Combating multidrug-resistant Plasmodium falciparum malaria[J]. FEBS J, 2017,284(16):2569-2578.
[5]	Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia[J]. N Engl J Med, 2008,359(24):2619-2620.
[6]	China Global Fund to Fight AIDS, Tuberculosis and Malaria[DB/OL]. http://www.China global fund.org/htm1.(in Chinese)
[6]	( 中国全球抗击艾滋病、结核和疟疾基金项目[DB/OL]. http://www.China global fund.org/htm1.)
[7]	Zhang L, Feng J, Zhang SS, et al. Analysis on the progress of malaria elimination and epidemic characteristics in 2017, China[J]. Chin J Parasitol Parasit Dis, 2018,36(3):201-209. (in Chinese)
[7]	( 张丽, 丰俊, 张少森, 等. 2017年全国消除疟疾进展及疫情特征分析[J]. 中国寄生虫学与寄生虫病杂志, 2018,36(3):201-209.)
[8]	Sun W. QSAR studies of bioactivity of isothiazolone and indole derivatives[D]. Qingdao: Ocean University of China, 2007. (in Chinese)
[8]	( 孙玮. 异噻唑啉酮和吲哚类化合物生物活性的定量构效关系研究[D]. 青岛: 中国海洋大学, 2007.)
[9]	Su XZ, Li J. Artemisinin and malaria: current understandings of drug activation, action, and resistance[J]. Chin Sci Bull, 2017,62(18):1928-1937. (in Chinese)
[9]	( 苏新专, 李剑. 青蒿素与疟疾: 药物激活、作用机理及抗药性的研究进展[J]. 科学通报, 2017,62(18):1928-1937.)
[10]	Verdrager J. Epidemiology of emergence and spread of drug-resistant falciparum malaria in Southeast Asia[J]. Southeast Asian J Trop Med Public Health, 1986,17(1):111-118.
[11]	Chu XW. Advances in drug resistance epidemiology and therapeutics of falciparum malaria[J]. Foreign Med Parasit Dis, 2003,30(4):152-157. (in Chinese)
[11]	( 楚心唯. 恶性疟的抗药性流行病学和治疗药物研究进展[J]. 国外医学(寄生虫病分册), 2003,30(4):152-157.)
[12]	Payne D. Spread of chloroquine resistance in Plasmodium falciparum[J]. Parasitol Today (Regul Ed), 1987,3(8):241-246.
[13]	Cui YQ, Cai XZ. Recent situation of chloroquine-resistant malaria in China[J]. Chin J Parasit Dis Control, 1995,8(4):303-304. (in Chinese)
[13]	( 崔宜庆, 蔡贤铮. 我国抗氯喹恶性疟近况[J]. 中国寄生虫病防治杂志, 1995,8(4):303-304.)
[14]	Feng XP, Liu DQ. Surveillance of antimalarial resistance and rational use of antimalarials in China[J]. Chin J Pathogen Biol, 2014,9(7):664-669. (in Chinese)
[14]	( 冯晓平, 刘德全. 我国恶性疟抗药性监测与抗疟药的合理应用[J]. 中国病原生物学杂志, 2014,9(7):664-669.)
[15]	Cai XZ. Status and epidemic characteristics of falciparum malaria in southern China[J]. Guangxi J Prev Med, 1995,1(3):133-135. (in Chinese)
[15]	( 蔡贤铮. 我国南方恶性疟疾现状和流行特征[J]. 广西预防医学, 1995,1(3):133-135.)
[16]	Liu DQ, Qiu CP, Liu RJ, et al. The extent of resistance of chloroquine resistant falcipahum malaria and the geographic distribution in China[J]. Chin J Parasitol Parasit Dis, 1986,4(2):81-85. (in Chinese)
[16]	( 刘德全, 邱持平, 刘瑞君, 等. 我国抗氯喹恶性疟的抗性程度及其地理分布[J]. 中国寄生虫学与寄生虫病杂志, 1986,4(2):81-85.)
[17]	Lin SG, Liu DQ, Zhuo KR, et al. Determination of sensitivity of Plasmodium falciparum to antimalarials in Ledong County, Hainan Province[J]. Chin Trop Med, 2005,5(8):1707-1708.(in Chinese)
[17]	( 林世干, 刘德全, 卓开仁, 等. 海南省乐东县恶性疟原虫对抗疟药的敏感性测定[J]. 中国热带医学, 2005,5(8):1707-1708.)
[18]	Liu DQ, Cai XZ, Ren DX, et al. Changes in chloroquine resistance of Plasmodium falciparum in Hainan Province[J]. Chin J Parasitol Parasit Dis, 1999,17(1):32-33. (in Chinese)
[18]	( 刘德全, 蔡贤铮, 任道性, 等. 海南省乐东县恶性疟原虫对氯喹抗性的变化[J]. 中国寄生虫学与寄生虫病杂志, 1999,17(1):32-33.)
[19]	Lin SG, Cai XZ, Zeng LH, et al. In vitro determination of susceptibility of Plasmodium falciparum to chloroquine, piperazine, paracetaquine, mefloquine and quinine in Ledong County, Hainan[J]. Hainan Med J, 1995,6(2):71-72. (in Chinese)
[19]	( 林世干, 蔡贤铮, 曾林海, 等. 乐东县恶性疟原虫对氯喹、哌喹、氨酚喹、甲氟喹及奎宁敏感性的体外测定[J]. 海南医学, 1995,6(2):71-72.)
[20]	Liu D, Cai X, Ren D, et al. Changes in chloroquine resistance of Plasmodium falciparum in Hainan Province[J]. Chin J Parasitol Parasit Dis, 1999,17(1):32-34.
[20]	( 刘丹, 蔡徐, 任道, 等. 海南省恶性疟原虫对氯喹的抗性变化[J]. 中国寄生虫学与寄生虫病杂志, 1999,17(1):32-34.)
[21]	Liu DQ, Feng XP, Yang HL, et al. Fluctuation in the resistance of Plasmodium falciparum to chloroquine in China[J]. Chin J Parasitol Parasit Dis, 2005,23(1):27-31. (in Chinese)
[21]	( 刘德全, 冯晓平, 杨恒林, 等. 我国恶性疟原虫对氯喹抗性的消长[J]. 中国寄生虫学与寄生虫病杂志, 2005,23(1):27-31.)
[22]	Guan YY, Tang LH, Hu L, et al. The point mutations in pfcrt and Pfmdr1 genes in Plasmodium falciparum isolated from Hainan Province[J]. Chin J Parasitol Parasit Dis, 2005,23(3):135-139. (in Chinese)
[22]	( 官亚宜, 汤林华, 胡铃, 等. 海南恶性疟原虫分离株Pfcrt和Pfmdr1基因点突变的研究[J]. 中国寄生虫学与寄生虫病杂志, 2005,23(3):135-139.)
[23]	Yu D, Jiang GF, Chen PQ. Analysis on the correlation between chloroquine resistance and pfmdr1 gene in Plasmodium falciparum isolates from Hainan Province[J]. Chin J Zoonoses, 2007,23(11):1143-1146. (in Chinese)
[23]	( 于丹, 江钢锋, 陈沛泉. 恶性疟原虫海南分离株pfmdr1基因与氯喹抗性的相关性分析[J]. 中国人兽共患病学报, 2007,23(11):1143-1146.)
[24]	Yang HL. Review and prospect of the application of antimalarial drugs in Yunnan[J]. J Pract Parasit Dis, 1999,7(4):174-176. (in Chinese)
[24]	( 杨恒林. 云南抗疟药应用的回顾与展望[J]. 实用寄生虫病杂志, 1999,7(4):174-176.)
[25]	Gu ZC, Zheng X. National malaria situation in 2000[J]. Chin J Parasitol Parasit Dis, 2001,19:257-259. (in Chinese)
[25]	( 顾政诚, 郑香. 2000年全国疟疾形势[J]. 中国寄生虫学与寄生虫病杂志, 2001,19:257-259.)
[26]	Che LG, Chen WC, Yang HL, et al. Investigation report on geographical distribution of chloroquine-resistant strains of Plasmodium falciparum in Yunnan Province[J]. Chin J Epidemiol, 1986,7:88. (in Chinese)
[26]	( 车立刚, 陈文才, 杨恒林, 等. 云南省恶性疟抗氯喹株地理分布调查报告[J]. 中华流行病学杂志, 1986,7:88.)
[27]	Yang HL. Discussion on monitoring and control measures of falciparum malaria in Yunnan Province[J]. Chin J Parasitol Parasit Dis, 1997,10(1):63-64. (in Chinese)
[27]	( 杨恒林. 云南省恶性疟的监测与防治对策探讨[J]. 中国寄生虫病防治杂志, 1997,10(1):63-64.)
[28]	Yang HL, Li XL, Gao BH, et al. Monitoring of susceptibility of Plasmodium falciparum to 7 antimalarial drugs in western part of China-Myanmar border[J]. Chin J Pathogen Biol, 2009,4(11):831-833. (in Chinese)
[28]	( 杨恒林, 李兴亮, 高百荷, 等. 中缅边境西段恶性疟原虫对7种抗疟药敏感性的监测[J]. 中国病原生物学杂志, 2009,4(11):831-833.)
[29]	Yang HL, Li CF, Yang YM, et al. Longitudinal observation of susceptibility of Plasmodium falciparum to chloroquine in southeastern Yunnan[J]. Chin J Pathogen Biol, 2008,3(12):917-919. (in Chinese)
[29]	( 杨恒林, 李春富, 杨亚明, 等. 云南东南部地区恶性疟原虫对氯喹敏感性纵向观察[J]. 中国病原生物学杂志, 2008,3(12):917-919.)
[30]	Zhu YJ, Chen MN, Xu YC, et al. Polymorphism analysis of the 72~76 coding sequence of Pfcrt gene exon2 region in Plasmodium falciparum[J]. Chin J Parasitol Parasit Dis, 2016,34(3):227-234. (in Chinese)
[30]	( 朱垚吉, 陈梦妮, 徐艳春, 等. 云南省恶性疟原虫Pfcrt基因exon2区72~76编码序列多态性的分析[J]. 中国寄生虫学与寄生虫病杂志, 2016,34(3):227-234.)
[31]	Kublin JG, Cortese JF, Njunju EM, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi[J]. J Infect Dis, 2003,187:1870-1875.
[32]	Mwai L, Ochong E, Abdirahman A, et al. Chloroquine resistance before and after its withdrawal in Kenya[J]. Malar J, 2009,8:106.
[33]	Dagnogo O, Ako AB, Ouattara L, et al. Towards a re-emergence of chloroquine sensitivity in C?te d’Ivoire?[J]. Malar J, 2018,17:413.
[34]	Liu DQ, Liu RJ, Zhang CY, et al. Current status of antimalarial susceptibility of Plasmodium falciparum in China[J]. Chin J Parasitol Parasit Dis, 1996,14(1):39-43. (in Chinese)
[34]	( 刘德全, 刘瑞君, 张春勇, 等. 我国恶性疟原虫对抗疟药敏感性的现状[J]. 中国寄生虫学与寄生虫病杂志, 1996,14(1):39-43.)
[35]	Chen L, Dai ZR, Cai XZ, et al. Changes in the epidemic situation of drug-resistant Plasmodium falciparum in Hainan Province, China[J]. J Guangzhou Univ Tradit Chin Med, 1998,15(1):35-37. (in Chinese)
[35]	( 陈林, 戴祖瑞, 蔡贤铮, 等. 我国海南省抗药性恶性疟流行情况的变迁[J]. 广州中医药大学学报, 1998,15(1):35-37.)
[36]	Huang QL, Zhou JX, Wu Z, et al. Continued observation of susceptibility of Plasmodium falciparum to chloroquine, quetiaquine, paracetamol, mefloquine and quinine in Hainan[J]. Chin J Parasitol Parasit Dis, 1988,12(31):19. (in Chinese)
[36]	( 黄祺林, 周洁娴, 伍柱, 等. 海南省恶性疟原虫对氯喹、喹哌、氨酚喹、甲氟喹及奎宁敏感性的继续观察[J]. 中国寄生虫学与寄生虫病杂志, 1988,12(31):19.)
[37]	Lin SG, Cai XZ, Zeng LH, et al. Drug sensitivity test of Plasmodium falciparum to chloroquine, piperaquine, amodiaquine, mefloquine and quinine in vitro in Ledong County, Hainan[J]. Hainan Med J, 1995,6:71-72.
[38]	Feng XP, Wang SQ, Lin SG, et al. Establishment and application of vitro microassay method for the sensitivity of Plasmodium falciparum to piperazine[J]. Chin Trop Med, 2015,15(8):924-927. (in Chinese)
[38]	( 冯晓平, 王善青, 林世干, 等. 恶性疟原虫对哌喹敏感性的体外微量法的建立与应用[J]. 中国热带医学, 2015,15(8):924-927.)
[39]	Fan B, Zhao W, Ma XW, et al. Sensitivity of Plasmodium falciparum to four antimalarial drugs in vitro in Yuxi, Yunnan Province[J]. Chin J Parasitol Parasit Dis, 1998,16(6):460-462. (in Chinese)
[39]	( 范波, 赵微, 马信文, 等. 云南省玉溪地区恶性疟原虫对四种抗疟药敏感性的体外测定[J]. 中国寄生虫学与寄生虫病杂志, 1998,16(6):460-462.)
[40]	Yang HL, Liu DQ, Huang KG, et al. In vitro determination of susceptibility of Plasmodium falciparum to chloroquine, paracetamol, piperazine, mefloquine and quinine in Yunnan[J]. Chin J Parasitol Parasit Dis, 1999,17(1):43-45. (in Chinese)
[40]	( 杨恒林, 刘德全, 黄开国, 等. 云南省恶性疟原虫对氯喹、氨酚喹、哌喹、甲氟喹和奎宁敏感性的体外测定[J]. 中国寄生虫学与寄生虫病杂志, 1999,17(1):43-45.)
[41]	Jia J, Fu J. Treatment of Plasmodium falciparum[J]. J Crit Care Int Med, 2005,11(1):1-2. (in Chinese)
[41]	( 贾杰, 符健. 恶性疟的治疗[J]. 内科急危重症杂志, 2005,11(1):1-2.)
[42]	Shang XM, Zhang QF. Advances on the prevalence and mechanism of artemisinin and piperazine resistance in Plasmodium falciparum[J]. Acad J Sec Milit Med Univ, 2018,39(11):1249-1254. (in Chinese)
[42]	( 尚晓敏, 张青锋. 恶性疟原虫青蒿素和哌喹耐药的流行现状及机制研究进展[J]. 第二军医大学学报, 2018,39(11):1249-1254.)
[43]	Na-Bangchang K, Congpuong K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand[J]. Tohoku J Exp Med, 2007,211(2):99-113.
[44]	Smithuis FM, Monti F, Grundl M, et al. Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar[J]. Trans R Soc Trop Med Hyg, 1997,91(4):468-472.
[45]	Smithuis F, Shahmanesh M, Kyaw MK, et al. Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar[J]. Trop Med Int Health, 2004,9(11):1184-1190.
[46]	Che LG, Zhang YL, Li XL, et al. Sensitivity of compound pyrimethamine of Plasmodium falciparum in Mengla County, Yunnan Province[J]. Chin J Parasit Dis Control, 1992,3:217. (in Chinese)
[46]	( 车立刚, 张有林, 李兴亮, 等. 云南省勐腊县恶性疟原虫对复方乙胺嘧啶敏感性观察[J]. 中国寄生虫病防治杂志, 1992,3:217.)
[47]	Meng F, Huang ZS, Chen C, et al. 7-year monitoring of the sensitivity of Plasmodium falciparum to pyraclopyridine/sulfadioxine/ethylpyrimidine[J]. Chin J Parasitol Parasit Dis, 1995,13(1):7. (in Chinese)
[47]	( 蒙锋, 黄在松, 陈昌, 等. 恶性疟原虫对咯萘啶/磺胺多辛/乙胺嘧啶敏感性的7年监测[J]. 中国寄生虫学与寄生虫病杂志, 1995,13(1):7.)
[48]	Cumming JN, Wang D, Park SB, et al. Design, synjournal, derivatization, and structure activity relationships of simplified, tricyclic, 1, 2, 4-trioxane alcohol analogues of the antimalarial artemisinin[J]. J Med Chem, 1998,41:952-964.
[49]	Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine[J]. Nat Med, 2011,17(10):1217-1220.
[50]	An J, Minie M, Sasaki T, et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs[J]. Ann Rev Med, 2017,68:317-330.
[51]	Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thai-land: a longitudinal study[J]. Lancet, 2012,379(9830):1960-1966.
[52]	Hien TT, Thuy-Nhien NT, Phu NH, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam[J]. Malar J, 2012,11:355.
[53]	Yang HL, Liu DQ, Huang KG, et al. In vitro determination of susceptibility of Plasmodium falciparum to artemisinin and tolnapyridine and chloroquine in Yunnan Province[J]. Chin J Parasitol Parasit Dis, 1997,15(5):292-296. (in Chinese)
[53]	( 杨恒林, 刘德全, 黄开国, 等. 云南省恶性疟原虫对青蒿素类药物及咯萘啶与氯喹敏感性的体外测定[J]. 中国寄生虫学与寄生虫病杂志, 1997,15(5):292-296.)
[54]	Yang CJ. Report of 1 case of falciparum malaria to artemether[J]. J Pract Parasit Dis, 2000,8(3):101. (in Chinese)
[54]	( 杨沧江. 1例恶性疟对蒿甲醚抗性报道[J]. 实用寄生虫病杂志, 2000,8(3):101.)
[55]	Feng J, Kong XL, Xu DM, et al. Investigation and evaluation of genetic diversity of Plasmodium falciparum Kelch13 polymorphisms imported from Southeast Asia and Africa in Southern China[J]. Front Public Health, 2019,7:95.
[56]	Yan H, Susana C, Ernest DB, et al. Artemisinin resistance-associated markers in Plasmodium falciparum parasites from the China-Myanmar border: predicted structural stability of K13 propeller variants detected in a low-prevalence area[J]. PLoS One, 2019,14(3):e0213686.
[57]	Su LG, Wang Y, Jia J. Artemisinin-resistant malaria 2 cases[J]. Chin J Pathogen Biol, 2001,14(1):66. (in Chinese)
[57]	( 苏林光, 王英, 贾杰. 抗蒿甲醚恶性疟2例[J]. 中国病原生物学杂志, 2001,14(1):66.)
[58]	Feng XP, Wang SQ, Lin SG, et al. Sensitivity monitoring of Plasmodium falciparum to artesunate in Hainan Province[J]. Chin Trop Med, 2015,15(10):1241-1243. (in Chinese)
[58]	( 冯晓平, 王善青, 林世干, 等. 海南省恶性疟原虫对青蒿琥酯的敏感性监测[J]. 中国热带医学, 2015,15(10):1241-1243.)
[59]	Fang Huang, Shannon TH, Christopher GJ, et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment[J]. J Infect Dis, 2015,212(10):1629-1635.